enter
last
six
month
presid
amaz
fast
time
move
soon
conven
la
jolla
icar
hand
rein
next
presid
also
know
result
elect
presidentelect
two
excel
candid
rhonda
cardin
johan
neyt
mani
year
particip
servic
isar
great
know
continu
attract
high
qualiti
peopl
lead
societi
forward
program
icar
come
togeth
nice
leadership
mark
prichard
enter
abstract
submiss
phase
use
new
electron
submiss
system
hope
everyon
find
site
easi
use
look
forward
feedback
best
part
new
submiss
websit
modifi
mani
featur
provid
much
better
experi
abstract
submitt
review
issu
isar
news
goe
press
hope
everyon
taken
moment
vote
new
offic
board
member
mani
year
vote
unfortun
remain
fairli
constant
around
membership
year
phil
furman
nomin
committe
solicit
excel
slate
candid
heavili
involv
isar
repres
futur
societi
hope
doubl
turnout
year
especi
sinc
vote
easi
use
system
set
webmast
andrea
brancal
past
year
also
seen
new
develop
isar
hope
produc
last
benefit
first
raj
kalkeri
form
initi
team
isar
ambassador
around
world
hard
work
solicit
new
sponsor
member
ambassador
program
util
isar
websit
facebook
social
media
spread
word
societi
annual
meet
would
like
get
involv
isar
strongli
recommend
join
ambassador
program
help
bring
peopl
meet
california
know
scientist
local
geograph
area
countri
would
benefit
attend
icar
greatli
benefit
new
idea
vision
anoth
import
develop
women
scienc
committe
solicit
applic
second
wi
scholarship
program
proudli
known
chu
famili
foundat
women
scienc
scholarship
thank
gener
fund
chu
famili
five
scholarship
award
applic
due
decemb
st
pleas
encourag
women
student
postdoc
submit
applic
unfortun
one
goal
presid
yet
materi
desir
use
wi
program
model
develop
way
ensur
young
scientist
abl
attend
icar
contribut
societi
last
six
month
offic
would
like
develop
committe
young
research
would
meet
icar
regular
confer
call
meet
discuss
societi
could
promot
particip
graduat
student
postdoc
young
investig
year
special
session
icar
featur
talk
young
member
shotgun
poster
present
fantast
euvirna
session
raleigh
also
held
young
investig
recept
meet
alway
one
favorit
hope
mani
young
scientist
around
world
want
get
involv
societi
membership
new
committe
work
promot
particip
icar
interest
pleas
email
get
start
hope
everyon
enjoy
informationpack
issu
isar
news
appreci
effort
public
committe
expand
four
issu
per
year
take
plenti
work
pull
issu
togeth
time
fashion
know
guest
editor
spend
lot
time
send
remind
submiss
articl
also
hope
newslett
begin
featur
news
item
submit
directli
membership
pleas
let
us
know
go
research
new
grant
public
product
summar
submit
abstract
appli
chu
famili
scholarship
volunt
ambassador
young
investig
program
look
forward
see
everyon
la
jolla
april
bob
buckheit
isar
presid
th
intern
confer
antivir
research
held
hilton
la
jolla
torrey
pine
hotel
la
jolla
california
sunday
april
th
thursday
april
st
venu
take
advantag
vibrant
research
commun
san
diego
area
meet
focu
latest
scientif
develop
antivir
research
also
emphas
interdisciplinari
natur
field
foster
collabor
provid
dedic
time
network
colleagu
icar
design
provid
opportun
virologist
chemist
pharmacologist
clinician
establish
maintain
close
collabor
relationship
need
discoveri
develop
effect
antivir
therapi
also
serv
stimul
innov
think
drug
develop
process
provid
specif
event
welcom
new
scientist
rank
help
establish
success
career
breadth
virus
discuss
topic
cover
provid
rich
environ
learn
scientist
differ
field
approach
problem
common
develop
antivir
therapi
confer
begin
session
drug
discoveri
develop
pm
sunday
april
th
rich
whitley
past
presid
isar
introduc
new
antivir
drug
discoveri
develop
center
fund
niaidnih
consortium
illustr
cooper
us
academ
institut
notforprofit
research
organ
commerci
partner
lead
rapid
develop
therapi
emerg
infect
interact
session
featur
present
maaik
evert
mark
denison
bob
bostwick
rob
jordan
th
icar
begin
pm
april
th
present
two
keynot
speaker
heinz
feldmann
md
phd
niaidnih
speak
ebola
viru
past
present
futur
review
research
origin
discoveri
filovirus
marburg
germani
present
west
african
epidem
also
provid
look
ahead
research
need
go
richard
h
scheuermann
phd
j
craig
venter
institut
speak
decod
viral
genom
next
gener
era
avail
wholegenom
sequenc
data
combin
standard
represent
viru
phenotyp
characterist
larg
number
viral
isol
allow
extens
genotypephenotyp
associ
studi
go
well
beyond
tradit
phylogenet
lineag
trace
lectur
demonstr
use
statist
genom
analysi
predict
influenza
viru
evolut
face
adapt
immun
identifi
novel
genet
determin
diseas
sever
enteroviru
first
two
symposia
take
place
morn
monday
april
th
highlight
recent
develop
use
structur
biolog
discov
develop
antivir
drug
session
organ
trio
prusoff
young
investig
award
winner
andrea
brancal
bruno
canard
erica
ollman
saphir
second
symposium
focus
dna
virus
organ
rhonda
cardin
graciela
andrei
held
morn
wednesday
april
th
featur
recent
advanc
therapi
includ
present
thoma
lion
adenoviru
infect
margaret
stanley
papillomaviru
david
bernstein
herpesviru
vaccin
timothi
kowalik
evolut
human
cytomegaloviru
year
icar
featur
poster
award
competit
tradit
continu
committe
chair
kathi
seleyradk
review
candid
award
past
year
competit
intens
program
committe
fortun
dedic
member
will
serv
import
subcommitte
cash
prize
award
categori
graduat
student
postdoctor
fellow
young
investig
awarde
also
opportun
present
work
shotgun
present
session
promin
poster
present
icar
reflect
excel
qualiti
offer
new
experienc
investig
highprofil
venu
present
work
icar
program
poster
present
mani
poster
place
isar
websit
member
review
materi
meet
program
committe
societi
commit
bring
reward
scientif
experi
respons
feedback
membership
committe
work
dilig
year
make
chang
meet
format
keep
best
featur
icar
ad
scientif
session
event
believ
heighten
experi
attende
follow
success
session
women
scienc
rome
icar
held
includ
panel
discuss
provid
advic
women
scientist
career
progress
societi
also
maintain
commit
newest
isar
member
sponsor
interact
career
forum
attende
meet
establish
scientist
profession
pharmaceut
biotech
academ
govern
sector
discuss
variou
career
option
addit
fee
career
forum
space
limit
attende
indic
interest
regist
meet
thank
gener
donat
chu
famili
mani
five
young
women
potenti
make
signific
contribut
field
antivir
research
receiv
scholarship
fund
may
use
attend
confer
visit
laboratori
take
cours
acquir
special
train
gener
career
develop
activ
one
applic
advisor
alreadi
fund
award
also
includ
membership
isar
commemor
certif
elig
applic
must
work
area
antivir
research
either
undergradu
graduat
student
five
year
cumul
postdoctor
experi
graduat
student
postdoc
must
member
isar
time
applic
applic
must
submit
cv
statement
exceed
two
page
describ
academ
achiev
goal
includ
explan
award
help
career
letter
support
research
project
director
depart
chair
center
director
fund
use
visit
anoth
scientist
laboratori
candid
must
submit
letter
head
lab
fund
use
attend
meet
take
cours
candid
must
provid
descript
activ
includ
link
onlin
inform
success
candid
demonstr
abil
independ
scientif
work
potenti
high
level
scientif
endeavor
leadership
skill
inform
appli
onlin
scholarship
go
http
wwwisaricarcom
pagewiscda
applic
must
submit
decemb
winner
select
cff
award
committe
march
st
award
present
th
icar
la
jolla
ilan
pronounc
elain
studi
veterinari
medicin
home
countri
mexico
first
research
project
join
group
develop
dna
vaccin
salmonella
infect
chicken
thesi
award
excel
veterinari
public
health
paho
howev
novel
swineorigin
viru
emerg
mexico
year
switch
focu
influenza
diagnost
epidemiolog
work
jointli
ministri
agricultur
fao
ilan
colleagu
valid
new
diagnost
test
screen
specimen
hundr
pig
farm
note
quickli
realiz
prefer
virolog
bacteriolog
ilan
move
netherland
enter
master
program
wageningen
univers
cellular
molecular
biotechnolog
focus
develop
nextgener
viral
vaccin
came
time
train
supervisor
drew
attent
european
train
network
ilan
moral
rna
viru
replic
antivir
drug
develop
euvirna
appli
phd
posit
consortium
becam
euvirna
fellow
conduct
research
dengu
viru
project
reflect
strong
interact
academ
scienc
pharmaceut
industri
daytoday
work
janssen
infect
diseas
vaccin
part
j
j
belgium
supervis
dr
marnix
van
loock
collabor
prof
johan
neyt
rega
institut
studi
respons
primari
human
mononuclear
cell
dengu
viru
infect
aim
establish
relev
vitro
model
antivir
drug
test
identifi
potenti
new
antivir
target
use
genomewid
transcriptom
analysi
primari
interest
studi
virushost
interact
would
like
contribut
field
antivir
drug
develop
identifi
new
target
prevent
treatment
also
strongli
commit
bring
new
knowledg
research
collabor
back
mexico
learn
link
basic
research
real
world
hope
make
posit
impact
individu
specif
woman
scientist
underrepres
group
develop
societi
scienc
attend
icar
raleigh
emphasi
given
connect
young
scientist
impress
network
prioriti
among
experienc
research
importantli
young
one
motiv
member
invest
much
time
effort
heart
session
women
scienc
career
discuss
network
time
alreadi
knew
andrea
brancal
mentor
euvirna
told
great
joy
felt
meet
learn
peopl
attend
icar
ask
could
becom
part
great
team
suggest
join
isar
commun
committe
help
manag
isar
facebook
page
twitter
media
could
say
ye
right
moment
inspir
friendli
environ
also
match
longstand
wish
work
scienc
commun
person
experi
social
network
scienc
start
follow
virolog
news
listen
vincent
racaniello
podcast
week
virolog
bu
go
antwerp
j
j
lab
extrem
valuabl
like
read
three
scientif
paper
one
hour
also
euvirna
train
program
attend
workshop
scienc
dissemin
societi
outreach
social
media
got
tip
trick
professor
experienc
team
blog
facebook
twitter
togeth
euvirna
fellow
prepar
blog
virus
antivir
research
review
professor
racaniello
gave
us
seriou
feedback
help
get
experi
kind
commun
one
main
activ
follow
scienc
news
sourc
scienc
natur
cdc
item
interest
member
post
isar
facebook
page
send
twitter
item
includ
link
sourc
short
comment
paragraph
explain
inform
also
contact
scientist
ask
permiss
use
figur
public
reward
typic
will
share
also
get
know
isar
incred
much
network
simpl
imag
bring
exampl
pictur
post
new
attende
recept
rome
icar
reach
almost
peopl
less
week
total
attende
isar
member
make
use
social
media
site
first
go
facebook
twitter
linkedin
sign
account
look
isar
network
like
page
facebook
follow
twitter
sign
everi
time
isar
post
someth
new
receiv
paragraph
call
post
facebook
tweet
twitter
interest
follow
link
complet
stori
isar
linkedin
page
mostli
manag
andrea
brancal
share
inform
isar
activ
facebook
account
post
inform
isar
page
use
post
space
may
respond
post
use
comment
space
sign
twitter
see
tweet
automat
notif
page
may
respond
new
tweet
two
way
retweet
share
follow
repli
post
comment
member
make
use
site
mani
way
use
isar
social
media
enhanc
commun
isar
member
promot
societi
activ
network
isar
member
other
antivir
research
find
remind
import
isar
deadlin
nomin
wi
award
icar
abstract
submiss
promot
ambassador
program
find
photo
past
icar
includ
poster
session
banquet
share
link
recent
public
exchang
inform
webpag
site
news
research
group
job
open
etc
encourag
give
tri
big
benefit
see
tri
best
thing
social
media
flexibl
offer
differ
resourc
person
agenc
commun
cdc
nasa
etc
great
success
use
social
media
would
like
inform
news
item
could
public
isar
social
network
email
ilanehernandezm
gmailcom
us
follow
news
ebola
epidem
awar
case
scottish
nurs
accident
infect
late
work
volunt
sierra
leon
treat
royal
free
hospit
london
discharg
past
januari
readmit
hospit
earli
octob
ebola
viru
infect
relaps
form
acut
mening
see
link
recurr
infect
exampl
increasingli
recogn
abil
ebola
viru
persist
anatom
site
rel
inaccess
immun
system
chamber
eye
central
nervou
system
semin
vesicl
fortun
known
exampl
date
recrudesc
involv
central
nervou
system
anoth
unusu
featur
case
antivir
medic
use
treat
nurs
new
gilead
compound
gilead
scienc
press
releas
oct
accord
isar
member
robert
jordan
head
gilead
team
develop
antivir
respiratori
virus
parent
compound
origin
discov
part
hepat
c
program
target
hcv
polymeras
strong
clinic
efficaci
sofosbuvir
especi
combin
ledipasvir
result
molecul
evalu
indic
includ
respiratori
virus
respiratori
syncyti
viru
rsv
stori
move
vitro
test
respiratori
virus
california
ebola
patient
highsecur
unit
london
provid
good
exampl
promis
drug
fasttrack
emerg
began
robert
decid
expand
test
gilead
nucleosid
nucleotid
rsv
two
member
paramyxoviru
famili
highli
virul
nipah
hendra
virus
establish
collabor
michael
lo
viral
special
pathogen
branch
cdc
atlanta
may
ebola
epidem
west
africa
began
spread
cdc
research
began
test
gilead
compound
filovirus
identifi
modifi
adenin
cnucleosid
ribos
analogu
novel
inhibitor
west
african
ebola
strain
ebola
speci
promis
vitro
data
led
collabor
gilead
usamriid
evalu
macaqu
model
lethal
ebola
viru
diseas
team
head
travi
warren
test
multipl
differ
treatment
dose
regimen
obtain
complet
protect
gave
daili
iv
dose
mgkg
begin
day
postinfect
anim
alreadi
virem
treatment
began
result
impress
usamriid
scienc
director
sina
bavari
state
press
releas
first
exampl
small
molecul
easili
prepar
made
larg
scale
show
substant
postexposur
protect
ebola
viru
nonhuman
primat
consequ
success
vivo
test
gilead
file
ind
past
juli
use
treat
ebola
viru
diseas
phase
test
healthi
human
volunt
began
august
scottish
nurs
hospit
earli
octob
suffici
data
obtain
support
compassion
use
drug
describ
robert
toma
employ
phosphoramid
prodrug
strategi
similar
sofosbuvir
recent
approv
tenofovir
alafenamid
prodrug
structur
enabl
molecul
permeat
cell
membran
rapidli
enter
cytoplasm
ester
bond
cleav
cellular
hydrolas
follow
chemic
catalyz
releas
phenol
yield
neg
charg
alanucleotid
conjug
cleav
amidas
releas
monophosph
nucleotid
cellular
kinas
quickli
produc
triphosph
molecul
incorpor
viral
rna
termin
synthesi
prodrug
strategi
thu
avoid
slow
first
phosphoryl
kinet
nucleosid
analogu
greatli
enhanc
intracellular
concentr
activ
triphosph
metabolit
addit
vitro
test
usamriid
univers
north
carolina
chapel
hill
found
also
activ
mer
coronaviru
interest
see
great
impact
treatment
ebola
mer
sever
rna
viral
infect
sofosbuvir
therapi
chronic
hepat
c
thank
travi
warren
robert
jordan
toma
cihlar
michael
lo
inform
edit
articl
http
newcluesintoebolaasillnurseimproveshtml
follow
success
euvirna
wwweuvirnaeu
whose
particip
receiv
mani
prize
icar
new
train
network
fund
european
union
antivir
mission
prepar
talent
young
research
lead
role
antivir
drug
discoveri
european
industri
academia
provid
multidisciplinari
intersector
train
program
may
lead
phd
degre
antivir
partnership
includ
seven
outstand
european
academ
partner
four
industri
partner
see
map
logo
leader
field
expertis
ensur
stateoftheart
train
skill
highli
complementari
three
academ
partner
utrecht
univers
leiden
univers
medic
center
univers
hospit
heidelberg
specialis
variou
aspect
molecular
virolog
four
cardiff
univers
daix
marseil
univers
leuven
univers
vienna
focu
identif
develop
novel
antivir
compound
strategi
four
industri
partner
includ
pharmaceut
r
compani
specialis
antivir
drug
discoveri
develop
aicuri
anoth
larg
compani
specialis
medicin
chemistri
prestwick
chemic
small
compani
pioneer
excit
novel
class
biopharmaceut
complix
small
busi
develop
antivir
drug
anim
virovet
compani
specialis
train
virolog
educ
contribut
expertis
programm
make
seriou
impact
next
gener
scientist
must
good
research
antivir
network
therefor
organis
train
relev
research
topic
viru
replic
structur
biolog
medicin
chemistri
wide
rang
transfer
skill
includ
teamwork
scienc
commun
dissemin
societ
outreach
ethic
biosafeti
innov
entrepreneurship
intellectu
properti
right
select
group
young
research
consist
fourteen
women
one
man
differ
countri
chosen
hundr
applic
world
excel
enthusiasm
laboratori
skill
potenti
becom
research
broad
view
desir
make
societ
impact
work
project
aim
gain
insight
antivir
drug
develop
select
group
virus
three
year
opportun
meet
young
interdisciplinari
intersectori
research
final
confer
hope
isar
inform
go
wwwantiviralsetneu
contact
project
manag
antiviralsetn
uunl
project
receiv
fund
european
union
horizon
research
innov
programm
mari
grant
agreement
year
scientist
rega
institut
made
import
contribut
develop
clinic
applic
antivir
herpesvirus
tradit
continu
creation
regavir
research
group
antivir
resist
graciela
andrei
robert
snoeck
program
director
would
like
make
sure
isar
member
awar
refer
center
offer
regavir
provid
clinician
rapid
genotyp
andor
phenotyp
clinic
isol
human
cytomegaloviru
herp
simplex
viru
varicellazost
viru
human
herpesviru
staff
also
provid
assist
interpret
result
treatment
option
sinc
regavir
perform
herpesviru
drugresist
test
recogn
belgian
refer
center
drugresist
dna
virus
thank
fund
belgian
nation
cancer
plan
interact
network
hospit
belgium
abroad
establish
continu
grow
regavir
carri
herpesviru
drugresist
test
assist
clinician
choic
adapt
therapi
promot
scientif
interact
network
rational
establish
regavir
lie
increas
import
antivir
therapi
herpesvirus
caus
signific
morbid
mortal
among
cancer
leukemia
patient
recipi
stem
cell
solid
organ
transplant
neonat
patient
genet
immun
defici
hiv
individu
virus
often
reactiv
caus
persist
infect
requir
prolong
treatment
increas
risk
select
drug
resist
mutant
remark
antiviralresist
hsv
remain
low
level
three
decad
immunocompet
individu
also
suscept
herpesviru
infect
immuneprivileg
site
eye
central
nervou
system
latter
lifethreaten
requir
rapid
therapeut
decis
except
acyclovir
oral
prodrug
valacyclovir
famciclovir
current
fdaapprov
drug
herpesvirus
associ
toxic
ganciclovir
oral
prodrug
valganciclovir
foscarnet
cidofovir
may
produc
hematolog
abnorm
primarili
neutropenia
anaemia
thrombocytopenia
ganciclovir
also
caus
long
termreproduct
toxic
cidofovir
foscarnet
nephrotox
altern
antivir
regimen
therefor
prefer
avoid
cumul
toxic
select
multidrugresist
virus
physician
typic
recogn
drugresist
herpesvirus
base
sign
infect
patient
regavir
aim
support
clinic
decisionmak
provid
prompt
character
viru
correct
use
avail
drug
necessari
avoid
select
multipleresist
virus
simultan
adjust
antivir
immunosuppress
therapi
enhanc
success
treatment
also
decreas
health
care
cost
inform
pleas
go
wwwregavirorg
contact
us
robertsnoeck
regakuleuvenb
gracielaandrei
regakuleuven
regavir
regakuleuvenb
march
antivir
research
publish
two
report
efficaci
novel
antivir
favipiravir
ebola
viru
infect
ifn
receptorknockout
mice
one
studi
steve
lever
group
dstl
porton
uk
show
aerosolinfect
mice
protect
treatment
begin
hour
viru
challeng
stephan
team
bernhard
nocht
institut
tropic
medicin
hamburg
found
intranasallyinfect
mice
protect
death
treatment
start
late
day
postinfect
mice
virem
show
biochem
evid
liver
injuri
probabl
demonstr
efficaci
favipiravir
late
cours
infect
paper
hamburg
lab
attract
wide
interest
download
time
articl
histori
avr
two
simultan
report
antiebola
activ
favipiravir
may
help
jumpstart
effort
deliv
drug
patient
west
african
epidem
openlabel
phase
ii
trial
began
month
later
two
treatment
center
guinea
collabor
inserm
san
see
wwwclinicaltrialsgov
first
report
antivir
drug
test
hamburg
lab
appear
stephan
colleagu
describ
util
rtpcr
drug
screen
howev
antivir
test
acceler
past
two
year
postdoc
lisa
oestereich
taken
lead
evalu
antivir
sever
highli
pathogen
virus
first
author
studi
favipiravir
treatment
ebolainfect
mice
followup
paper
colleagu
hamburg
franc
perform
mathemat
model
effect
favipiravir
therapi
kinet
ebola
viru
replic
use
data
earlier
paper
doctor
thesi
bni
lisa
develop
new
mous
model
lassa
fever
recent
publish
paper
cowork
describ
use
model
demonstr
favipiravir
activ
lassa
viru
alon
combin
ribavirin
lisa
colleagu
also
examin
efficaci
favipiravir
ribavirin
arbidol
mice
infect
crimeancongo
hemorrhag
fever
viru
stephan
research
hamburg
date
began
postdoctor
fellowship
heinrich
pett
institut
studi
hepat
b
viru
direct
career
underw
major
chang
accept
posit
research
group
leader
bni
shift
focu
tropic
medicin
viral
hemorrhag
fever
publish
first
paper
lassa
fever
report
case
import
germani
sinc
becom
world
author
diseas
author
coauthor
articl
stephan
becam
head
depart
virolog
bni
director
lab
collabor
centr
addit
antivir
drug
test
stephan
group
perform
routin
diagnost
servic
differ
tropic
emerg
virus
test
sampl
patient
year
includ
case
import
europ
also
routin
carri
isol
biobank
lassa
ebola
virus
provid
academia
compani
within
european
viru
archiv
http
wwweuropeanvirusarchivecom
sinc
laboratori
virolog
success
collabor
irrua
specialist
teach
hospit
nigeria
focus
develop
rapid
diagnost
research
pathogenesi
immunolog
lassa
fever
collabor
research
project
way
guinea
ghana
isar
member
interest
influenza
ebola
viru
infect
know
two
websit
provid
access
wealth
scientif
resourc
diseas
wwwfilovircom
wwwinfluenzavircom
find
link
recent
news
item
scientif
public
offici
report
notic
upcom
confer
use
inform
site
interfac
world
social
network
microblog
via
twitter
manual
curat
annot
filter
deliv
time
updat
scientif
news
particular
filovir
provid
daili
coverag
ebola
epidem
west
africa
tweet
news
alert
almost
real
time
luca
zinzula
max
planck
institut
munich
websit
brainchild
luca
zinzula
creat
phd
candid
lab
enzo
tramontano
cagliari
sardinia
concept
filovir
born
luca
found
despit
exist
numer
virusrel
databas
internet
inform
present
highli
dispar
limit
specif
subfield
disciplinari
area
especi
ebola
marburg
virus
middl
ground
extrem
level
detail
repositori
intend
specialist
superfici
frequent
incorrect
inform
nonscientif
websit
luca
concept
bring
togeth
inform
wide
rang
authorit
thirdparti
resourc
real
time
singl
web
environ
everi
tool
would
readili
access
navig
goal
creat
virtual
space
research
could
find
abstract
latest
public
pinpoint
locat
latest
outbreak
retriev
genom
sequenc
protein
structur
hear
upcom
confer
everyth
click
away
filovir
went
live
januari
one
year
later
influenzavir
went
onlin
twin
site
focus
influenza
virus
creat
two
websit
luca
realiz
would
need
help
maintain
fortun
obtain
support
two
colleagu
massimiliano
orsini
bioinformatician
expert
genom
databas
cristian
romagnani
biologist
move
field
network
system
big
data
analysi
luca
present
websit
poster
icar
rome
recognit
effort
benefit
virolog
commun
recogn
antivir
research
first
recipi
annual
award
promis
antivir
research
luca
nativ
sardinia
begin
scientif
studi
spent
sever
year
work
profession
scuba
diver
frequent
involv
rescu
conserv
activ
endang
marin
speci
special
focu
monitor
infecti
diseas
casualti
hang
fin
undergradu
work
biochemistri
virolog
univers
cagliari
continu
doctor
research
enzo
tramontano
receiv
phd
univers
rome
tor
vergata
studi
character
dsrnabind
activ
zair
ebolaviru
protein
sinc
begin
luca
postdoctor
fellow
lab
wolfgang
baumeist
maxplanck
institut
biochemistri
martinsri
munich
learn
cryoelectron
microscopi
use
techniqu
investig
role
protein
filoviru
replic
innat
immun
antagon
addit
current
work
cryoem
luca
widerang
scientif
interest
includ
express
purif
character
recombin
viral
protein
vitro
assay
proteinrna
bind
immun
evas
highli
pathogen
rna
virus
enzo
publish
remark
thorough
review
articl
avr
latter
topic
zinzula
l
tramontano
e
strategi
highli
pathogen
rna
virus
block
dsrna
detect
rigilik
receptor
hide
mask
hit
antivir
re
liev
associ
professor
laboratori
virolog
chemotherapi
rega
institut
katholiek
universiteit
leuven
belgium
clearli
happi
univers
leuven
began
undergradu
studi
spent
entir
career
rega
institut
passion
virolog
began
master
studi
thesi
recombin
hepat
b
vaccin
chanc
invit
interview
erik
de
clercq
charm
posit
enthusiast
attitud
toward
young
research
immedi
decid
phd
work
lab
time
acycl
nucleosid
phosphon
anp
discov
lucki
abl
work
preclin
develop
doctor
project
focus
pharmacokinet
efficaci
antiretrovir
anp
anim
model
direct
mentor
jan
balzarini
also
close
interact
team
pragu
collabor
gilead
first
demonstr
vivo
efficaci
oral
prodrug
tenofovir
soon
becam
lead
hiv
blocker
end
phd
period
got
chanc
compil
insight
success
drug
class
highli
cite
review
articl
antivir
chemistri
chemotherapi
start
postdoctor
period
left
field
antiretrovir
anp
work
adefovir
tenofovir
easi
move
antidna
viru
anp
like
cidofovir
collabor
colleagu
graciela
andrei
robert
snoeck
johan
neyt
new
research
focus
two
dna
virus
adenoviru
import
pathogen
especi
recipi
organ
stem
cell
transplant
unfortun
much
neglect
antivir
drug
develop
also
becam
involv
foundat
aim
keep
neglect
viru
research
agenda
mani
year
member
scientif
board
dna
viru
period
assist
first
two
graduat
student
focu
virushost
interact
adenoviru
combat
novel
inhibitor
also
period
appoint
academ
teach
teach
virolog
immunolog
mention
scientif
board
foundat
main
role
give
advic
antivir
therapi
moment
howev
perform
drug
develop
sinc
need
new
therapi
clear
clinic
patient
treat
classic
antiherpet
agent
ganciclovir
foscarnet
brincidofovir
also
appear
promis
new
drug
infect
work
sever
year
dna
virus
decid
shift
focu
influenza
becom
evid
current
antivir
neuraminidas
inhibitor
suffici
new
drug
clearli
need
virolog
viewpoint
new
viru
technicalexperiment
standpoint
could
reli
expertis
acquir
virus
group
two
main
topic
influenza
antivir
inhibitor
polymeras
complex
inhibitor
viral
entri
first
encompass
inhibitor
pa
cellular
factor
associ
viral
polymeras
regard
influenza
pa
endonucleas
drive
forc
behind
network
academ
research
expertis
medicin
chemistri
structur
biolog
enzymolog
virolog
cell
cultur
biochem
data
high
direct
relev
develop
pa
inhibitor
drug
class
sever
pharmaceut
compani
work
inhibitor
viral
polymeras
good
fit
lab
concept
continu
line
research
career
second
topic
includ
inhibitor
hemagglutinin
fusion
inhibitor
compound
interfer
cellular
factor
involv
viru
entri
compound
inhibit
endocytosi
proteolyt
activ
ha
influenza
viru
hemagglutinin
amaz
research
topic
even
though
protein
studi
extens
still
knowledg
gap
regard
link
receptor
signal
biochem
detail
proteolyt
cleavag
speci
adapt
henc
use
hemagglutinin
inhibitor
tool
resolv
basic
scientif
question
drug
develop
hemagglutinin
easi
target
given
subtypedepend
variabl
structur
influenza
virus
evolv
rapidli
easili
develop
drug
resist
believ
inhibitor
cellular
factor
high
clinic
relev
strategi
explain
recent
review
articl
influenza
viru
entri
inhibitor
influenza
team
seven
cowork
pi
respons
project
design
mentor
graduat
student
grant
applic
write
paper
also
network
medicin
chemist
mainli
european
univers
collabor
design
synthes
inhibitor
interest
translat
aspect
research
expert
anp
hypothes
compound
may
act
like
product
inhibitor
hypoxanthineguanin
phosphoribosyltransferas
crucial
enzym
plasmodium
parasit
mycobacteria
valid
concept
proven
collabor
team
luke
guddat
brisban
australia
late
pragu
sinc
first
joint
public
becom
total
new
concept
antiparasit
drug
design
project
success
mani
highimpact
paper
citat
current
role
network
pharmacolog
aspect
relat
prodrug
design
cell
permeabl
cytotox
strongli
believ
pharmacologist
look
potenti
new
applic
inhibitor
concept
instanc
nucleosid
analogu
success
anticanc
antivir
drug
equal
relev
field
antiparasit
antibacteri
therapi
consid
pharmacologistvirologist
nt
medicin
chemistri
reveal
interact
molecul
viral
target
need
understand
sar
inhibitor
basic
knowledg
chemistri
requir
goal
find
innov
drug
inhibit
virus
elucid
mechan
action
aim
discov
new
inhibitor
may
shortterm
clinic
relev
use
inhibitor
understand
virus
nice
balanc
appli
basic
research
isar
member
know
andrea
stand
cardiff
colleagu
salvator
ferla
winner
prusoff
young
investig
award
us
familiar
direct
career
increasingli
explor
use
computerbas
method
design
new
antivir
anticanc
drug
andrea
involv
antivir
research
began
undergradu
project
romano
silvestri
lab
universita
la
sapienza
rome
investig
novel
nonnucleosid
rt
inhibitor
receiv
degre
doctor
work
chri
mcguigan
lab
welsh
school
pharmaci
focus
design
synthesi
evalu
novel
antivir
nucleosid
becam
research
associ
continu
staff
member
finish
undergradu
degre
militari
servic
want
doctor
research
medicin
chemistri
possibl
abroad
appli
sever
place
uk
us
chri
mcguigan
repli
right
away
excit
join
chri
lab
continu
work
antivir
field
particular
happi
opportun
work
nucleosid
analogu
difficult
chemistri
sometim
satisfi
work
plan
aspect
found
satisfi
alway
want
career
activ
independ
research
consid
lucki
achiev
best
part
job
possibl
interact
wide
varieti
collabor
differ
field
never
bore
alway
learn
someth
new
cardiff
univers
school
particular
dynam
stimul
place
alway
commit
excel
particular
ideal
place
foster
collabor
develop
new
idea
time
seven
patent
file
base
project
contribut
ten
student
receiv
phd
supervis
current
group
three
postdoc
five
graduat
student
involv
varieti
collabor
project
receiv
fund
public
privat
sector
certain
extent
chemist
like
work
specif
field
especi
solid
collabor
biologist
also
happi
move
differ
direct
indic
belov
compound
could
interest
anoth
therapeut
context
point
view
comput
chemistri
fidel
specif
research
area
even
tenuou
method
neutral
appli
almost
drug
design
project
exampl
collabor
project
span
way
design
antivir
chikungunya
viru
model
simul
small
peptid
treatment
gastrointestin
diseas
new
approach
use
research
appli
sever
differ
structurebas
methodolog
includ
molecular
dock
homolog
model
molecular
dynam
cours
also
make
use
tradit
organ
synthet
method
classic
medicin
chemistri
approach
design
synthes
novel
potenti
drug
recent
made
strateg
decis
expand
research
develop
area
molecular
model
softwar
particular
becom
interest
research
relat
comput
interact
interfac
human
comput
would
improv
qualiti
silico
drug
design
led
group
develop
hapticdriven
molecular
model
simul
present
icar
miami
come
medicin
chemistri
background
complet
new
research
field
quickli
becom
fascin
recent
attend
interest
faraday
discuss
meet
molecular
simul
visual
anyon
interest
understand
new
softwar
method
head
look
confer
paper
http
pubsrscorgenjournalsjournalissuesfd
issu
typecurr
develop
antivir
share
common
ground
anticanc
field
nucleosid
analogu
import
drug
field
fact
common
aspect
increasingli
see
drug
design
hit
target
host
cell
pathway
find
new
applic
antivir
field
clearest
exampl
cyclindepend
kinas
inhibitor
roscovitin
develop
anticanc
agent
also
shown
antivir
activ
effort
develop
new
drug
often
lead
disappoint
sometim
unexpectedli
success
experi
disappoint
common
emot
research
face
career
learn
forget
failur
quickli
use
move
forward
impetu
sever
small
big
disappoint
last
year
tend
rememb
success
potenti
interact
virtual
screen
hit
compound
protein
lead
reduc
motil
malign
cell
block
metastasi
moment
excit
project
focus
develop
antimetastat
agent
base
recent
discov
role
protein
cancer
cell
motil
especi
mammari
cancer
began
virtual
screen
simul
four
year
ago
sinc
becom
foundat
stone
spinoff
compani
tiziana
life
scienc
http
wwwtizianalifesciencescom
list
aim
section
london
stock
exchang
major
focu
career
drug
discoveri
flavivirus
princip
diseas
antivir
need
although
vaccin
best
countermeasur
flavivirus
approv
vaccin
current
avail
yellow
fever
japanes
enceph
tickborn
enceph
virus
antivir
drug
need
agent
lack
approv
vaccin
dengu
viru
denv
top
prioriti
within
categori
even
diseas
vaccin
avail
yellow
fever
low
vaccin
rate
mani
endem
region
mean
effect
therapi
still
need
ye
mani
lesson
learn
hcv
drug
discoveri
exampl
pangenotyp
coverag
high
resist
barrier
sofosbuvir
show
clear
advantag
nucleotid
analog
approach
would
ideal
singl
compound
could
identifi
inhibit
broad
spectrum
flavivirus
compar
hepat
c
chronic
diseas
treat
least
week
durat
therapi
dengu
flavivir
diseas
expect
week
toxic
barrier
much
lower
past
decad
academia
industri
made
effort
develop
inhibitor
flavivirus
especi
denv
variou
approach
taken
approach
proven
challeng
lim
et
al
nucleosidenucleotid
analog
exhibit
attract
featur
broadspectrum
coverag
high
resist
barrier
advantag
alreadi
demonstr
adenosin
analog
denv
cell
cultur
mous
model
yin
et
al
howev
number
scientif
hurdl
still
need
address
exampl
antidenv
drug
cell
tissu
viru
replic
acut
phase
infect
human
could
engin
compound
select
load
onto
site
interest
nucleosidenucleotid
approach
pleas
refer
recent
review
topic
chen
et
al
proteas
inhibitor
appear
less
promis
contrast
hcv
proteas
peptidomimet
drug
success
two
positivelycharg
amino
acid
residu
locat
immedi
upstream
flaviviru
proteas
cleavag
site
make
approach
challeng
effort
need
develop
denv
proteas
inhibitor
compound
target
denv
envelop
capsid
protein
also
report
physicalchem
properti
inhibitor
prohibit
develop
type
compound
inhibitor
xie
et
al
remain
explor
drug
target
host
factor
requir
viral
replic
alpha
glucosidas
inhibitor
play
critic
role
diseas
develop
mast
cell
stabil
worth
investig
addit
smallmolecul
drug
therapeut
antibodi
explor
denv
flavivirus
antibodi
activ
across
serotyp
recent
report
cell
cultur
mous
model
potent
serotypespecif
antibodi
also
report
approach
requir
least
four
antibodi
inhibit
one
denv
serotyp
expect
enter
clinic
trial
soon
vaccin
antivir
complement
diseas
control
intervent
recent
result
frontrunn
dengu
vaccin
shown
great
promis
despit
certain
limit
eg
weak
efficaci
denv
serotyp
cydtdv
vaccin
ongo
vaccin
trial
continu
unravel
mani
question
dengu
diseas
immun
respons
human
inform
facilit
antivir
develop
especi
antivir
candid
reach
clinic
trial
realli
excit
wit
particip
effort
translat
knowledg
dengu
diseas
benefit
patient
safeti
efficaci
two
import
paramet
therapeut
travel
dengueendem
area
prophylact
dose
may
suffici
prevent
diseas
short
visit
peopl
live
endem
area
like
multipl
treatment
cours
either
prophylact
therapeut
need
make
drug
safeti
even
import
success
develop
hcv
drug
benefit
dengu
antivir
develop
success
therapeut
develop
denv
expect
facilit
discoveri
flavivirus
due
similar
among
flaviviru
protein
would
ideal
inhibitor
denv
would
crossinhibit
virus
even
lower
efficaci
inhibitor
would
good
start
point
chemic
modif
improv
efficaci
flavivirus
strategi
remain
experiment
investig
rapid
pointofcar
diagnost
essenti
especi
recruit
dengu
patient
earli
acut
infect
clinic
trial
like
acut
viral
infect
treatment
window
dengu
patient
short
feasibl
short
treatment
window
experiment
address
use
safe
efficaci
compound
clinic
set
efficaci
safeti
establish
one
could
conceiv
treat
febril
patient
area
ongo
dengu
outbreak
without
confirm
diagnosi
opportun
find
especi
excit
help
build
partnership
utmb
lead
research
institut
china
especi
wuhan
institut
virolog
academi
scienc
open
china
first
laboratori
hope
establish
work
relationship
exchang
scientist
collabor
research
project
year
mark
th
anniversari
discoveri
australia
antigen
subsequ
identifi
hepat
b
viru
surfac
antigen
baruch
blumberg
colleagu
nation
institut
health
fox
chase
cancer
center
provid
specif
serum
marker
hepat
b
discoveri
led
rapid
progress
multipl
area
includ
develop
diagnost
test
improv
safeti
blood
transfus
product
first
hepat
b
vaccin
abil
detect
asymptomat
infect
also
reveal
huge
number
peopl
around
world
chronic
hepat
b
relationship
termin
cirrhosi
hepatocellular
carcinoma
th
anniversari
particularli
special
event
hepat
b
foundat
director
isar
member
tim
block
tim
wife
joan
establish
foundat
public
health
advocaci
outreach
organ
commit
help
peopl
hepat
b
creat
institut
hepat
viru
research
independ
nonprofit
organ
dedic
find
therapi
improv
qualiti
live
affect
hepat
b
liver
cancer
dr
blumberg
maintain
offic
institut
death
pass
institut
renam
honor
blumberg
institut
locat
within
pennsylvania
biotechnolog
center
life
scienc
incub
doylestown
pa
home
addit
hepat
b
blumberg
institut
also
strong
program
antivir
rna
virus
filoviru
antivir
program
produc
novel
imino
sugar
shown
efficaci
anim
model
merck
compani
donat
collect
natur
product
includ
schere
plough
legaci
institut
one
divers
druggabl
librari
natur
product
world
institut
scientist
screen
antivir
anticanc
lead
make
collect
avail
research
institut
blumberg
institut
activ
potenti
interest
isar
member
includ
establish
profession
univers
pharmaceut
biotech
industri
may
offer
faculti
appoint
fund
space
develop
idea
recent
colleg
graduat
may
perform
research
fellowship
work
mentor
assign
project
graduat
student
master
phd
program
may
obtain
adjunct
appoint
univers
pennsylvania
drexel
univers
nearbi
institut
mark
th
anniversari
discoveri
australia
antigen
blumberg
institut
sponsor
collect
invit
articl
antivir
research
symposium
paper
review
rang
novel
therapi
hepat
b
horizon
access
http
wwwjournalselseviercomantiviralresearchsymposiasymposiumhepatitisb
isar
member
bart
tarbet
report
two
new
project
utah
state
univers
first
respons
recent
outbreak
enteroviru
midwestern
usa
china
area
iar
receiv
contract
extramur
niaidnih
develop
mous
model
enteroviru
infect
use
evalu
therapeut
bart
direct
studi
fund
first
two
year
support
model
develop
success
addit
fund
cover
drug
test
project
someth
new
iar
octob
bart
met
dr
emmanuel
assana
professor
veterinari
medicin
cameroon
central
africa
annual
meet
intern
societi
vaccin
discuss
possibl
research
collabor
decid
appli
grant
establish
laboratori
cameroon
surveil
detect
emerg
reemerg
zoonos
govern
minist
livestock
fisheri
anim
industri
support
propos
recommend
lab
includ
nation
program
prevent
fight
emerg
reemerg
zoonos
part
usaid
program
global
health
secur
emerg
pandem
threat
although
award
yet
offici
recent
word
usaid
propos
submit
implement
partner
one
health
central
eastern
africa
grant
approv
bart
help
set
lab
provid
train
biosafeti
biosecur
personnel
cameroon
train
virolog
diagnost
iar
utah
veterinari
diagnost
laboratori
bart
would
enjoy
hear
isar
member
suggest
larger
scope
activ
project
studi
infecti
diseas
transmiss
wildlifelivestock
interfac
environment
driver
emerg
infecti
diseas
year
nomin
committe
charg
find
two
candid
posit
presidentelect
two
post
secretari
six
candid
three
posit
board
director
given
time
talent
societi
would
make
excel
board
member
elect
held
isar
websit
begin
novemb
th
conclud
hope
member
vote
abl
make
difficult
choic
among
slate
excel
candid
rhonda
join
parkedavi
pharmaceut
senior
scientist
supervis
evalu
antiherpesviru
compound
anim
model
also
part
hiv
entri
inhibitor
program
pfizer
merger
join
chemocentryx
inc
work
chemokin
therapeut
diseas
vaccin
strategi
join
faculti
cincinnati
children
hospit
medic
center
research
focus
murin
cytomegaloviru
pathogenesi
latenc
model
human
cytomegaloviru
current
nihfund
sinc
serv
copi
nih
contract
evalu
novel
antivir
vaccin
strategi
cmv
hsv
anim
model
join
isar
activ
attend
present
icar
serv
poster
judg
herpesviru
cochair
current
member
financ
membership
public
committe
serv
isar
execut
board
past
four
year
also
member
women
scienc
committe
led
effort
develop
women
scienc
mentor
program
johan
neyt
full
professor
virolog
faculti
medicin
univers
leuven
ku
leuven
belgium
teach
medic
virolog
school
medicin
dentistri
focu
laboratori
develop
novel
antivir
vaccin
strategi
author
peer
review
paper
hold
sever
patent
sixteen
peopl
obtain
phd
degre
guidanc
bachelor
master
student
train
laboratori
editor
antivir
research
editori
board
sever
journal
johan
cofound
cso
ku
leuven
spinoff
okapi
scienc
nv
biotech
compani
develop
antivir
veterinari
use
cso
virovet
wwwvirovetcom
new
ku
leuven
spinoff
current
incorpor
research
topic
cover
laboratori
univers
leuven
includ
develop
novel
antivir
strategi
number
rna
virus
includ
flavivirus
hepat
c
dengu
other
picornavirus
enteroand
rhinovirus
alphavirus
chikungunya
other
paramyxovirus
rsv
other
rabi
norovirus
hepat
e
viru
well
novel
thermost
dna
vaccin
technolog
johan
attend
icar
sinc
receiv
william
prusoff
young
investig
award
also
serv
board
member
chair
membership
committe
graciela
main
scientif
activ
includ
unravel
mode
action
novel
antivir
molecular
mechan
drug
resist
herpesvirus
poxvirus
molecular
anticanc
mechan
action
nucleotid
analogu
develop
organotyp
epitheli
raft
cultur
studi
epitheliotrop
virus
particip
setup
regavir
translat
research
platform
type
drugresist
herpesvirus
immunocompromis
patient
fail
antivir
therapi
member
isar
sinc
elect
secretari
member
editori
board
antivir
research
plo
one
kara
carter
year
experi
virolog
research
discoveri
develop
antivir
agent
follow
undergradu
research
stanford
univers
collabor
chiron
develop
diagnost
receiv
phd
virolog
univers
chicago
laboratori
dr
bernard
roizman
identifi
novel
gene
elucid
mechan
protein
product
perform
postdoctor
studi
harvard
univers
brigham
women
hospit
laboratori
dr
elliiott
kieff
focus
ebvinduc
transcript
chang
infect
b
cell
effect
transform
move
praeci
pharmaceut
led
drug
discoveri
